Corneal Implants Market Size, Share, Growth, Trends, and Global Industry Analysis: By Type Of Implant (Refractive Corneal Implantable Device, Corneal Reshaping Implantable Device, Small Aperture Corneal Implantable Device), By End-user (Hospitals, Ophthalmic Clinics, Retail Ophthalmic Stores) and Region

Corneal Implants Market size was valued at US$ 356.61 million in 2023 and is poised to grow at a CAGR of 7.8% from 2024-2030. Corneal Implants also called corneal inlays are optical devices inserted into the cornea to improve vision. The main purpose of optical devices is to improve the near vision and reduce the need for reading spectacles in adults with presbyopia. Corneal implants are one of the options for the rectification of declined near vision in people with presbyopia who desire to have a spectacle-independent superior vision for all distances. Corneal implantable devices have also been used for the correction of hyperopia, myopia, and astigmatism. As per to the Eye Bank Association of America (EBAA), the number of endothelial keratoplasty cases in the U.S. was over 23,000 in 2012 and corneal surgery was the most adopted choice to avoid blindness and restore the damaged eye.

According to EBAA, presbyopia affects nearly 80-90% population over the age of 40 years worldwide. The global corneal implants market continues to witness positive growth owing to increased cataract development over the age of 65, increasing life expectancy, and a rising geriatric population would is expected to fuel demand for ocular implants throughout the forecast. An increase in the number of keratoplasty cases and corneal surgeries will boost market growth over the forecast period. The market for ocular implants is driven by technological advances in implants like multifocal intraocular lens technology and rising awareness about aesthetics among the young patient population expected to fuel the market for ocular implants throughout the forecast.

However, potential side effects or damage associated with the use of ocular implants to the eye, and the dearth of a skilled workforce to perform the implantation procedures may hamper the growth of the ocular implants market throughout the forecast. As per the EU National Statistics, it is estimated that over 209 Mn Europeans are suffering from presbyopia and it is projected that nearly half of the European population will suffer from presbyopia by 2030 which may propel the Corneal Implants market during the forecast period. Spain's market for corneal implants will expect lucrative growth over the forecast period. The growth is attributed to consumers being willing to spend for eye care in the country.

Key Developments

• Dec 2024: Glaukos Corporation, focused on novel therapies for ocular diseases and disorders including glaucoma, corneal disorders, and retinal diseases, announced that the U.S. Food and Drug Administration (FDA) approved its New Drug Application (NDA) for a single administration per eye of iDose® TR (travoprost intracameral implant) 75 mcg, a prostaglandin analog indicated for the reduction of intraocular pressure (IOP) in patients with ocular hypertension (OHT) or open-angle glaucoma (OAG).   
• June 2024: CorneaGen has announced the commercial launch of Corneal Tissue Addition for Keratoplasty, CTAK-an innovative, extremely effective solution to corneal contouring for keratoconic eyes. Developed by CorneaGen in partnership with CTAK LLC and Ziemer, CTAK offers patient-ready, gamma-irradiated sterile, non-immunogenic corneal tissue segments, laser cut and customized to patients' specific cone severity and location.              
• Nov 2023: Pantheon Vision (PV) has received $2.5 million in seed funding from KeraLink International (KLI) to start developing new bioengineered corneal implants as part of the quest to eliminate blindness caused by the cornea worldwide, for both developed and low- and middle-income countries (LMICs).